Does anyone know what he is promoting? I’m giving away the ticker symbol of the #1 stock to buy now… using the same system that bears my name on every Bloomberg terminal on Wall Street But today, I’m going public with something I’ve never said on national air… not in any of my appearances on […]
According to Banyan Hill, two secretive billionaires funded a project to defeat rogue AI, and their breakthrough is now critical to Microsoft’s alliance with OpenAI – the creators of ChatGPT. Any idea what they’re talking about?
Weiss Ratings has issued a “Buy” on a stock that’s leading the AI revolution in one of the most profitable industries in the world. I share the details in my just-released special briefing, “The Next AI Bonanza.” Martin D. Weiss, PhD, investorinteldaily.com
Which company? This is not Ozempic, Advil, or vitamin D… It’s an entirely new class of medicine that could earn you an absolute FORTUNE. Because not only can it make you smarter, make you stronger, and extend your life span by as much as 20 years… It’s also the most profitable drug in human history… […]
Gonna keep this one short because after 55 minutes of hype, in my opinion this is just his answer to Joel Litman’s program announced yesterday — each one has their five or 6 biotech stocks poised to have thousand percent gains. Lango’ s program is HIGH VELOCITY STOCKS, same list price 5000, lower ‘today’ price […]
Louis Navellier presented his “Emergency Cash Bubble Briefing” on March 14, 2024 as a way to promote his “BREAKTHROUGH STOCKS” (an update to an existing program). His premise is ‘the $8.8B AI bubble will burst and people in on this new group of assets will realize generational wealth,’ (so get out of cash and into […]
Porter STansberry and Joel Litman presented on March 26. The theme of the presentation was “Historic Market Anomaly, 1 in 20 year money making opportunity.” But it evolved into their taking about Biotech stocks and how some of them are trading for less than the cash value of the company, calling them Net-Net companies. They […]
Latest pitch from Altimetry and Stansberry about the Bio-Tech sector being deeply undervalued and their five favorite negative EV stocks set to soar when interest rates drop.
I just listened to the program “Urgent Stock Market Update with Porter Stansberry and Prof. Littman about net net biotech stocks due to raised interest rates. I would be interested in hearing Travis’ thoughts on the 5 Best Negative EV Biotech Opportunities in 2024 and any other comments. Thank you. Macrame Momma
Doe anyone know what he is speaking of in this presentation?
Getting this out a bit early because everything’s closed up for the Good Friday holiday tomorrow. What’s up with the Real Money Portfolio? We did get a few final 2023 reports… and that led to some investment decisions on my part. The Boston Omaha (BOC) annual report came in a little later than last year, […]
We’ve seen tons of stories about GLP-1 drugs, and have watched the big sellers of those drugs, Novo Nordisk (NVO) and Eli Lilly (LLY), become by far the largest pharma companies in the world (Lilly, in particular, has touched a $750 billion valuation… closing in on the “Magnificent Seven” tech stocks and breaking into the […]
The world of psychedelics was briefly exciting for investors, mostly back around 2019-2020 or so, when everyone was looking for the next version of the cannabis bull market (remember that?)… and as potential for legalization of some drugs, like psilocybin (“magic mushrooms”), seemed to be in the wind, and old hallucinogenic or psychedelic compounds were […]
Few years ago they recommended getting out from Nexo… this was after Celsius, SBF, etc. I see Nexo is still alive and couldn’t find anything that could suggest a collapse. I once read here that someone considered Nexo as a Suisse Bank comparatively speaking. Does anybody know if Palm Beach, or others, recommend staying away […]
would this be the GLP 1 drugs by Lilly and Novo?
Received an email from News.Alex Data Stream Any insight into this Tease
Tiny biotech wins 75 billion dollar patent. On March 1, 2022, a tiny biotech firm won a patent on a new treatment that can “Cut & Paste” disease from your body. The Wall Street Journal reports this company is “transforming medicine.”
Jinxed says: